Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 206

The DOI matches its Crossref record.

CYTOKINE CASCADES IN ACUTE GRAFT-VERSUS-HOST DISEASE1

Krenger, Werner, Hill, Geoffrey R., Ferrara, James L.M. · 1997 · Transplantation

Abstract

Bone marrow transplantation (BMT*) is currently indicated in the treatment of a number of malignant and non-malignant diseases, including acute and chronic leukemias, myelomas, lymphomas, aplastic anemia, solid tumors, and severe immunodeficiencies. Allogeneic BMT, i.e., transplantation between two genetically nonidentical individuals, is associated with serious side effects; its most common complication is graft-versus-host disease (GVHD). Recently, the use of unrelated donors and HLA-nonidentical family members has resulted in increased frequencies of severe GVHD (1). The development of acute and chronic GVHD and the immunosuppression used for GVHD prophylaxis represent significant risk factors for bacterial, fungal, and viral infections (2). Studies of experimental and clinical allogeneic BMT have shown that immunologically competent T cells must be present in the transplanted graft for GVHD to occur (3). Depletion of T cells or T-cell subsets prevents GVHD and eliminates the need for further immunosuppression but is associated with a higher rate of graft failure and increased incidence of leukemic relapse, resulting in equivalent disease-free survival for patients who receive conventional prophylaxis (4). GVHD thus remains a major barrier to allogeneic BMT for a variety of diseases, and further elucidation of the pathophysiological mechanisms involved is critical to its wider application. Advances in basic immunology during the last decade have demonstrated how interactions between immunologically competent cells are governed by cytokines, and much recent research has focused on the roles of these mediators in the pathogenesis of acute GVHD. In this Overview, we examine current evidence that dysregulated cytokine production occurs as a cascade during sequential monocyte and T-cell activation and is responsible for many of the manifestations of acute GVHD. Cytokine dysregulation can be conceptualized as three sequential phases (Fig. 1). Phase 1 is initiated by the conditioning of the host, which induces inflammatory processes in recipient tissues. Donor T-cell activation by host alloantigens and subsequent cytokine secretion in phase 2 are facilitated by the events of phase 1. The T cell-derived cytokines of phase 2 activate distal inflammatory mediators which, in synergy with T and natural killer (NK) cell-mediated cytotoxicity, produce the systemic morbidity of GVHD-associated immunosuppression (phase 3). Each of these three phases is considered in detail below. It should be noted that these mechanisms have been most clearly delineated in mouse BMT models. Although there is preliminary work to suggest that these cascades are important in clinical GVHD (5), detailed analysis of human tissue is required. PHASE 1: HOST CONDITIONING Induction of Inflammatory Cytokines during Host Conditioning Agents used for BMT conditioning, which often includes total body irradiation and/or chemotherapy, are important variables in the etiology of acute GVHD and other transplant-related complications for two major reasons. First, ionizing radiation activates host cells to secrete increased levels of inflammatory cytokines, e.g., tumor necrosis factor (TNF)-α and interleukins (IL) 1 and 6 (6, 7). Increased systemic levels of these cytokines are detectable within a few hours after conditioning, and their excess can lead to endothelial cell damage (8), which contributes to increased activation of donor T cells present in the donor marrow inoculum. Facilitation of T-cell activation by inflammatory cytokines may occur via their direct stimulatory action on T cells, or indirectly via enhanced antigen presentation or enhanced intercellular adhesion (reviewed in (9) and (10)). The conditioning regimen may have a second important role in the induction of GVHD: injury to the mucosal surface of the gastrointestinal tract may enable bacterial breakdown products, such as endotoxin or lipopolysaccharide (LPS), to enter the splanchnic circulation. LPS may subsequently stimulate preactivated gut-associated macrophages to release TNF-α and IL-1 (11) (see below). Clinically, the early appearance of increased TNF-α levels during phase 1 appears to be of value for the prediction of the subsequent severity of complications and overall survival after clinical allogeneic BMT (7, 12). A recent phase II study demonstrates that TNF-α blockade during conditioning can delay the onset of acute GVHD and decrease the incidence of severe disease (13). These data suggest that inhibitors of inflammatory cytokines may be efficacious when used in the immediate peritransplant period. It is possible that multiple cytokines contribute to this process, including those of macrophage and T-cell origin (e.g., TNF-α, IL-1, and interferon [IFN]-γ), offering several targets for inhibition. This may be particularly important in the unrelated donor or HLA-mismatched, related BMT setting, where current immunosuppression strategies are less than optimal. PHASE 2: DONOR T

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-199708270-00001

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 206

Metadata

Authors
Krenger, W., Hill, G. R., & Ferrara, J. L. M.
Venue
Transplantation
Published
1997-08
Volume
64
Issue
4
Pages
553-558
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2071927386
Cited by
206
References
0
FWCI
6.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CYTOKINE CASCADES IN ACUTE GRAFT-VERSUS-HOST DISEASE1. https://app.cochat.ai/papers/10.1097/00007890-199708270-00001
The paper
Krenger, W., Hill, G. R., & Ferrara, J. L. M. (1997). CYTOKINE CASCADES IN ACUTE GRAFT-VERSUS-HOST DISEASE1. Transplantation. https://doi.org/10.1097/00007890-199708270-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.